COMPANY INTRODUCTION - INNOSER
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Company Introduction
JUNE 2021
Service Portfolio InnoSer offers a range of contract research services 01
within 4 main therapeutic fields
COMPANY INTRODUCTION | JUNE 2021
Cardio-metabolic Nephrology neurology Oncology
Our Mission
02
With the highest standards of customer care we support and
accelerate drug development in oncology, nephrology,
cardiometabolic and neurodegenerative diseases
Globally supporting, pharmaceutical
and biomedical companies in the
(pre)clinical chain with;
- Highly reliable, well
COMPANY INTRODUCTION | JUNE 2021
characterised in vivo and in vitro
disease models,
- Big data,
- State-of-the-art imaging
- Histopathology services
Our Story
03
Founded in 2012, InnoSer is an innovative and dynamic
CRO supporting drug discovery and preclinical development
2012 2015 2016 2017 2018
Start in vivo Start InnoSer BV AAALAC Preclinical facility VLAIO PDXO- &
COMPANY INTRODUCTION | JUNE 2021
operations in collaboration accreditation operational, Eurostar
with TNO (Leiden) InnoSer Belgium Cystarrest- Grant
2019 2020
AAALAC accreditation Roll out of in vivo capabilities
(Diepenbeek) (BLI, Echography)
- New in vitro lab -Launch of Digital
operational Pathology services
Our Pillars
04
InnoSer offers a range of contract research services
in vivo and in vitro within three main pillars
Preclinical Services Pathology Services
ADPKD Compound Digital Pathology Preclinical,
Nephrology Screening (Pkd1 cKo Veterinary
model) & Humane
Neurodegenerative PD Compound Screening
(Human Midbrain
Organoids)
PDX/O Screening
COMPANY INTRODUCTION | JUNE 2021
(Immuno-) Oncology Platform
Syngeic assays
Orthotopic models
In Vivo Services
In vivo Imaging Bioluminescence Imaging
High Throughput Contract Breeding
Echography
Sanitation
Infectious Diseases BSL 3 Facility Cryo-preservation
Leiden
Why Choose
05
InnoSer?
InnoSer offers an outstanding collection of well-characterized models that
specifically emphasize on personalized medicines, to benefit
the patient.
Highly skilled team and state-of-the-art in-vivo and in-vitro
facilities in NL and BE
- AAALAC facility under SPF conditions
COMPANY INTRODUCTION | JUNE 2021
- Offering imaging and (digital) pathology services
Unique and very well characterized models
- Only commercially available conditional knock-out
mouse for Pkd1
- First commercially available Midbrain Organoid platform
Why Choose
06
InnoSer?
With the highest standards of customer care we support and
accelerate drug development in oncology, nephrology,
cardiometabolic and neurodegenerative diseases
Experienced service provider in-vivo able to offer complementary
research models
- Extensive network in EU life-sciences
COMPANY INTRODUCTION | JUNE 2021
Very strong research and development pipeline
- PDX/O platform (PDX/O) including liquid tumors (non-
Hodgkin’s lymphoma) (Lemonaid)
- At forefront of OoC technologies: Brain on Chip for
Alzheimer (MINDMAP) and ALS (Nano+) and Heart on
Chip (Heart-Chip II)
In Vivo
Services
COMPANY INTRODUCTION | JUNE 2021
07
In Vivo
08
InnoSer operates two AAALAC-accredited facilities;
in Diepenbeek (B) and Leiden (NL)
InnoSer offers several key in-vivo Maintenance of genetically altered
research services at its 1200 m2 SPF (GA) models in collaboration with EU
laboratories partner
‘Made-to-Measure’ preclinical studies - Cryo-Preservation Services
- non-GLP studies - Sanitation Services
- Studies into infectious diseases - - Rederivation Services
COMPANY INTRODUCTION | JUNE 2021
BSL 1, BSL 2 & BSL 3
Contract Breeding Services
Colony Management Services
Imaging
09
Now adding imaging capabilities to offer a deeper (kinetic)
assessment of compound efficacy across our models
New: High-resolution Ultrasound and Photoacoustic New: Bioluminescence Imaging (BLI)
Imaging
- To assess tumorgenicity in mice
- Real-time read-outs of malignancies, kidney cysts
inoculated with luciferase expressing
and/or blood-vessels.
cells
- High throughput analysis of volumetrics,
COMPANY INTRODUCTION | JUNE 2021
vascularization, perfusion
- Can be used with various echo probes for a larger
spectrum of analyses
- Now being validated for use with ADPKD mouse-model
- Allowing for de-risking during long P18 and P40 studiesServices
Nephrology
COMPANY INTRODUCTION | JUNE 2021
10Nephrology
11
Tamoxifen inducible conditional knock-out of Pkd1
in mice
Autosomal Dominant Polycystic Genetically and phenotypically relevant
Kidney Disease affects 1 in 2500 model for ADPKD in mice
people
- Mutations in Pkd1 (polycystine-1) resulting in - Developed by Prof. D.J.M. Peters at
85% of patients the LUMC (Leiden, NL)
- Formation of fluid filled cysts ultimately - Conditional knock-out of Pkd1
COMPANY INTRODUCTION | JUNE 2021
resulting in kidney failure - Specifically affecting the kidneys
- Extrarenal cysts in liver and pancreas, InnoSer manages an established and stable
hypertension and cardiovascular abnormalities breeding colony of Pkd1-cKO mice
Provided PKD screening services to
(bio)pharmaceutical customers worldwideModels
12
Three distinct models are available – these have been characterized
and validated in-house to provide robust and reliable outcomes
P10: P18: P40:
- Specially affects the distal - More accurate representation of human - Closest to a human phenotype
nephron. pathology - Slowest progression, affecting
COMPANY INTRODUCTION | JUNE 2021
- Treatment duration of 6 - Slowly progressive phenotype, affecting proximal nephron.
weeks. all segments. - Treatment duration of 22 to 52 weeks
- Treatment duration of 13 weeks. (P40,slow).
InnoSer is offering relevant pathological markers for each model
- Expanding this with imaging (echography) soonServices
Neurology
COMPANY INTRODUCTION | JUNE 2021
13Neurology
14
Parkinson’s Disease currently has no cure, creating a need for
better translation from preclinical models to in patient efficacy
InnoSer offers the first fully Organoids are functional
characterized human midbrain microtissues
organoid for compound screening
- Recapitulating electrophysiology with working
- Developed by Prof. J. Schwamborn at synapses & neuromelanin formation
Université Luxembourg
COMPANY INTRODUCTION | JUNE 2021
- hiPSc derived, can be generated from healthy
individuals and PD-patients
- Compounds may be screened using a fully Organoids contain high
concentrations of dopaminergic
automated (high-throughput) pipeline neurons (TH+)
- Deep characterization based on machine
- Also: GABAergic-, glutamatergic-neurons,
learning algorithms
astrocytes & oligodendrocytesVariations
15
InnoSer offers three main approaches with numerous
model variations
1) Patient-Specific Cells (G2019S - LRRK2) 2) Patient-Derived hMO’s
Reduction in dopaminergic neurons only observed in 3D Generated from somatic material PD-patients
PD-phenotype rescued with LRRK2 inhibitor
- Increased TH, improved branching complexity
3) Toxin induced (6-OHDa) models
SNCA, PINK1 and GBA models available on request
6-OHDa treatment results in PD-phenotype
- Dose dependent inhibition of TH
COMPANY INTRODUCTION | JUNE 2021Screening
16
This hMO platform is ready for high-throughput
screening applications
High-Content Imaging AI Algorithms Deep Cell Analysis Cell Phenotype
COMPANY INTRODUCTION | JUNE 2021Services
Oncology
COMPANY INTRODUCTION | JUNE 2021
17Oncology
18
Poor attrition rates in cancer research leads to
high costs for drug development
Limitation in conventional models Better translation from models in the
preclinical phase improves odds of patient
trial success
- Genetic drift in cell-lines results in poor
translatability - Patient-derived models preserve patient
- Important cell-cell interactions needed to variability to offer more accurate predictions
maintain physiology lack in 2D
COMPANY INTRODUCTION | JUNE 2021Oncology
19
Poor attrition rates in cancer research leads to
high costs for drug development
InnoSer offers its PDX/O platform for PDX/O platform offers well-defined models
compound screening for each part of your preclinical pipeline
- Developed in collaboration with LUMC (NL)
- Early stage (In-Vitro): Patient-Derived Organoids
Jessa hospital (BE) and uHasselt (BE)
(PDO, 3D)
- This platform combines patient-derived
- Late stage (In-Vivo): Patient-Derived Xenografts
COMPANY INTRODUCTION | JUNE 2021
organoids (PDO) and xenografts (PDX)
(PDX)
- Aimed at capturing and recapitulating patient
variability across various malignanciesPDX/O
20
InnoSer’s PDX/O platform offers a selection of
(rare) malignancies
Both PDX’s and PDO’s are thoroughly InnoSer is building a Biobank with
validated throughout multiple primary and metastatic patient
passages materials
- Lung (NSCL)
- DNA Hotspot, RNA-Seq and full
- Pancreas
pathologic characterization
- Liver
- Various assays and read-outs are
- Esophageal (at LUMC)
COMPANY INTRODUCTION | JUNE 2021
available both in-vitro and in-vivo
- Gastric carcinomas (at LUMC)
- Coming soon: Non-Hodgkin lymphoma
(Lemonaid)
Now: we’re seeking early adopters to validate these models collaborativelyPartnering
21
InnoSer is a flexible partner that enables your (immuno-) oncology
research projects
Combining approaches may greatly shorten development time of promising
lead compounds
InnoSer has a lot of experience in providing screening services in oncology
COMPANY INTRODUCTION | JUNE 2021
Especially:
- Syngeneic subcutaneous or orthotopic tumor growth models
- Analyses of immune populations in tumors, blood markers
- PBMC models for T-cell exhaustion in patient populations
- PK/PD new compounds in naive / tumor bearing mice, MTD determinationYou can also read
